214 related articles for article (PubMed ID: 17346282)
1. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action.
Sharabi A; Azulai H; Sthoeger ZM; Mozes E
Immunology; 2007 Jun; 121(2):248-57. PubMed ID: 17346282
[TBL] [Abstract][Full Text] [Related]
2. Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide.
Lapter S; Marom A; Meshorer A; Elmann A; Sharabi A; Vadai E; Neufeld A; Sztainberg Y; Gil S; Getselter D; Chen A; Mozes E
Arthritis Rheum; 2009 Dec; 60(12):3744-54. PubMed ID: 19950283
[TBL] [Abstract][Full Text] [Related]
3. Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide.
Sharabi A; Lapter S; Mozes E
J Autoimmun; 2010 Mar; 34(2):87-95. PubMed ID: 19596183
[TBL] [Abstract][Full Text] [Related]
4. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta.
Sharabi A; Zinger H; Zborowsky M; Sthoeger ZM; Mozes E
Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8810-5. PubMed ID: 16735466
[TBL] [Abstract][Full Text] [Related]
5. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase.
Rapoport MJ; Sharabi A; Aharoni D; Bloch O; Zinger H; Dayan M; Mozes E
Clin Immunol; 2005 Dec; 117(3):262-70. PubMed ID: 16257268
[TBL] [Abstract][Full Text] [Related]
6. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis.
Sharabi A; Haviv A; Zinger H; Dayan M; Mozes E
Clin Immunol; 2006 May; 119(2):146-55. PubMed ID: 16503419
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients.
Mauermann N; Sthoeger Z; Zinger H; Mozes E
Clin Exp Immunol; 2004 Sep; 137(3):513-20. PubMed ID: 15320900
[TBL] [Abstract][Full Text] [Related]
8. The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cells.
Sharabi A; Mozes E
J Immunol; 2008 Sep; 181(5):3243-51. PubMed ID: 18713995
[TBL] [Abstract][Full Text] [Related]
9. Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations.
Elmann A; Sharabi A; Dayan M; Zinger H; Ophir R; Mozes E
Arthritis Rheum; 2007 Jul; 56(7):2371-81. PubMed ID: 17599765
[TBL] [Abstract][Full Text] [Related]
10. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.
Sthoeger ZM; Sharabi A; Molad Y; Asher I; Zinger H; Dayan M; Mozes E
J Autoimmun; 2009 Aug; 33(1):77-82. PubMed ID: 19346102
[TBL] [Abstract][Full Text] [Related]
11. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation.
Luger D; Dayan M; Zinger H; Liu JP; Mozes E
J Clin Immunol; 2004 Nov; 24(6):579-90. PubMed ID: 15622442
[TBL] [Abstract][Full Text] [Related]
12. The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients.
Sthoeger ZM; Sharabi A; Dayan M; Zinger H; Asher I; Sela U; Mozes E
Hum Immunol; 2009 Mar; 70(3):139-45. PubMed ID: 19280712
[TBL] [Abstract][Full Text] [Related]
13. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus.
Mozes E; Sharabi A
Autoimmun Rev; 2010 Nov; 10(1):22-6. PubMed ID: 20659591
[TBL] [Abstract][Full Text] [Related]
14. The role of CD4CD25 T cells in autoantibody production in murine lupus.
Hsu WT; Suen JL; Chiang BL
Clin Exp Immunol; 2006 Sep; 145(3):513-9. PubMed ID: 16907921
[TBL] [Abstract][Full Text] [Related]
15. A subset of CD4+ T cells expressing early activation antigen CD69 in murine lupus: possible abnormal regulatory role for cytokine imbalance.
Ishikawa S; Akakura S; Abe M; Terashima K; Chijiiwa K; Nishimura H; Hirose S; Shirai T
J Immunol; 1998 Aug; 161(3):1267-73. PubMed ID: 9686587
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of stromal cell-derived factor-1alpha-induced T cell chemotaxis by a peptide based on the complementarity-determining region 1 of an anti-DNA autoantibody via up-regulation of TGF-beta secretion.
Sela U; Hershkoviz R; Cahalon L; Lider O; Mozes E
J Immunol; 2005 Jan; 174(1):302-9. PubMed ID: 15611253
[TBL] [Abstract][Full Text] [Related]
17. Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus.
Lee JH; Wang LC; Lin YT; Yang YH; Lin DT; Chiang BL
Immunology; 2006 Feb; 117(2):280-6. PubMed ID: 16423064
[TBL] [Abstract][Full Text] [Related]
18. Regulation of immune function by calorie restriction and cyclophosphamide treatment in lupus-prone NZB/NZW F1 mice.
Sun D; Krishnan A; Su J; Lawrence R; Zaman K; Fernandes G
Cell Immunol; 2004 Mar; 228(1):54-65. PubMed ID: 15203320
[TBL] [Abstract][Full Text] [Related]
19. In-vitro generation and characterisation of murine CD4+CD25+ regulatory T cells with indirect allospecificity.
Tsang J; Jiang S; Tanriver Y; Leung E; Lombardi G; Lechler RI
Int Immunopharmacol; 2006 Dec; 6(13-14):1883-8. PubMed ID: 17161341
[TBL] [Abstract][Full Text] [Related]
20. Protection against renal disease in (NZB x NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide.
Ferrera F; Hahn BH; Rizzi M; Anderson M; Fitzgerald J; Millo E; Indiveri F; Shi FD; Filaci G; La Cava A
Arthritis Rheum; 2007 Jun; 56(6):1945-53. PubMed ID: 17530718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
